Clinical Value of the Changes of ER, PR, HER2 and Ki-67 Expressions Before and After Neoadjuvant Chemotherapy in Breast Cancer
[1]
Zheng Gu, Department of Breast Cancer Surgery, Tangshan People's Hospital, Tangshan, China;.
[2]
Yaqi Wang, Department of Breast Cancer Surgery, Tangshan People's Hospital, Tangshan, China;.
[3]
Jiwei Hu, Department of Breast Cancer Surgery, Tangshan People's Hospital, Tangshan, China;.
[4]
Jinghua Zhang, Department of Breast Cancer Surgery, Tangshan People's Hospital, Tangshan, China;.
[5]
Jie Ma, Department of Breast Cancer Surgery, Tangshan People's Hospital, Tangshan, China;.
[6]
Jingjing Chen, Department of Breast Cancer Surgery, Tangshan People's Hospital, Tangshan, China;.
[7]
Zhichao Cui, Department of Breast Cancer Surgery, Tangshan People's Hospital, Tangshan, China;.
[8]
Meng Chang, Department of Breast Cancer Surgery, Tangshan People's Hospital, Tangshan, China;.
[9]
Lei Wang, Department of pathology, Tangshan People's Hospital, Tangshan, China.
Objective: To investigate clinical value of the changes of ER, PR, HER2 and Ki-67 expressions before and after neoadjuvant chemotherapy in breast cancer. Methods: From January 2011 to December 2016, the clinical data of 72 patients with locally advanced breast cancer, which received neoadjuvant chemotherapy were collected. The relationship between curative effect of neoadjuvant chemotherapy and clinical feature, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), and Ki-67 were analyzed retrospectively. Results: In the 72 cases of breast cancer, the total effective rate of neoadjuvant chemotherapy was 76.4% (55/72). Among them, CR, PR an SD were 16.7% (12/72), 59.7% (43/72) and 23.6% (17/72) respectively. No progressed case was found. Pathological complete remission (pCR) was in 9.72% (7/72). There were significant relationships between the clinical effective rate of neoadjuvant chemotherapy and the size of primary tumor, ER, PR, HER 2 and Ki-67 (P<0.05). Pathological complete remission was correlated with the status of ER, and PR (P<0.05). The changes of ER, PR, HER2 and Ki-67 were in 22.2%, 25.0%, 15.3% and 55.6% respectively before and after between neoadjuvant chemotherapy in breast cancer. There were significant correlation between the curative effect of neoadjuvant chemotherapy and changes of ER, PR, Ki-67 (P<0.05). There were no significant correlation between HER2 and curative effect of neoadjuvant chemotherapy. Conclusion: The ER, PR, HER2 and Ki-67 expressions show significant changes after neoadjuvant chemotherapy in breast cancer. ER, PR and Ki-67 would predict the curative effects of neoadjuvant chemotherapy.
Breast Cancer, Neoadjuvant Chemotherapy, Curative Effect
[1]
Biswas T, Efird JT, Prasad S, et al. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer [J]. Oncotarget, 2017, 8 (68): 112712-9.
[2]
Matsubara N, Mukai H, Naito Y, et al. Prognostic significance of reduction rate of Ki-67 after neoadjuvant chemotherapy in breast cancer patients with non-pCR [J]. Journal of Clinical Oncology, 2013, 31 (15).
[3]
Yang L, Zhong X, Pu T, et al. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy [J]. World Journal of Surgical Oncology, 2018, 16 (1): 51.
[4]
Harvey JM, Clark GM, Osborne CK, et al. Harvey JM, Clark GM, Osborne CK, Allred DCEstrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. J Clin Oncol 17 (5): 1474-1481 [J]. Journal of Clinical Oncology, 1999, 17 (5): 1474-81.
[5]
Wolff AC, Hammond MEH, Schwartz JN, et al. Guideline Summary: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor HER2 Testing in Breast Cancer [J]. Journal of Oncology Practice, 2007, 3 (1): 48-50.
[6]
Curtit E, Nerich V, Mansi L, et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis [J]. Oncologist, 2013, 18 (6): 667-74.
[7]
Gahlaut R, Bennett A, Fatayer H, et al. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression – Implications for the practising oncologist ☆ [J]. European Journal of Cancer, 2016, 60 (40) 8.
[8]
Zhao XC, Liang LI. Analysis of ER, PR, HER2, Ki-67 Expression Changes before and after the Neoadjuvant Chemotherapy of Breast Cancer [J]. China & Foreign Medical Treatment, 2017.
[9]
Loo CE, Rigter LS, Pengel KE, et al. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer [J]. Breast Cancer Research Bcr, 2016, 18 (1): 82.
[10]
Kolberg HC, Loevey G, Akpolatbasci L, et al. Targeted intraoperative radiotherapy tumour bed boost during breast conserving surgery after neoadjuvant chemotherapy in HER2 positive and triple negative breast cancer [J]. Reviews on Recent Clinical Trials, 2017, 12 (5): 318.
[11]
Chen XS, Wu JY, Huang O, et al. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy [J]. Oncology Reports, 2010, 23 (5): 1213-20.
[12]
Chen HR, Wu YT, Yu QB, et al. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer [J]. World Journal of Surgical Oncology, 2017, 15 (1): 189.
[13]
Wu W, Deng H, Rao N, et al. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial [J]. Trials, 2017, 18 (1): 497.
[14]
Ekholm M, Bendahl PO, Fern㶠M, et al. Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII: 2pre Trial [J]. Journal of Clinical Oncology, 2016, 34 (19): 2232-8.
[15]
Carlo P, Macpherson Iain RJ, Yan K, et al. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [J]. Oncotarget, 2016, 7 (11): 13209-20.
[16]
Matsubara N, Mukai H, Fujii S, et al. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer [J]. Breast Cancer Research & Treatment, 2013, 137 (1): 203-12.
